Navigation Links
Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
Date:4/16/2013

IRVING, Texas, April 16, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced that five data presentations related to blood-based circulating microvesicles (cMVs) will be presented this week at the 2013 International Society for Extracellular Vesicles (ISEV) meeting in Boston, Mass.

This research is part of the company's development efforts for its Carisome® platform, which uses a novel, proprietary method to rapidly and accurately identify and characterize potential disease-associated circulating microvesicles found in the blood. This unique and promising technology platform has the potential for direct clinical utility in early diagnostic testing and disease and treatment monitoring in cancer patients.

"Caris Life Sciences is pioneering major advances in understanding and characterizing circulating microvesicles, as well as determining the ways in which their application to patient care could increase the accuracy of diagnosis and better guide therapeutic planning," said Joachim Schorr , Ph.D., Chief Scientific Officer at Caris Life Sciences. "We believe our research efforts in this area hold tremendous potential across a broader array of diseases, including cancer, and represent a groundbreaking opportunity to fundamentally change the way medicine is practiced."

ISEV will feature the following Caris Life Sciences poster presentations, along with one oral presentation:

Wednesday, April 17, 2013

  • Abstract 135, Reference # 2279393: Daniel Holterman , Tassilo Hornung , Srividya Kankipati , et al. Identification and Implications of Transcription Factors in Circulating Microvesicles from Cancer Patients. Arlington- Berkley Room , Poster Session 1, 8:30 a.m.
  • Abstract 129, Reference # 2279338: Tassilo Hornung , Srividya Kankipati , Candace Alva , et al. Effect of Colonoscopy on Circulating Microvesicles. Arlington- Berkley Room , Poster Session 1, 8:30 a.m.
  • Abstract 130, Reference # 2279344: Jorge L. Schettini , Mukesh Maheshwari , Krunal Desai , et al., et al. Multi-Color Flow Cytometric Analysis of Cancer-Derived Microvesicles Reveals a Unique Subpopulation Ratio in Plasma from Prostate Cancer Patients. Arlington- Berkley Room , Poster Session 1, 8:30 a.m.

Friday, April 19, 2013

  • Abstract 136, Reference # 2279403: Kirk M. Brown , Meredith P. Millis , Shannon E. Smith , et al. Circulating Microvesicles Contain Critical Elements of the RISC Complex. Statler Room , Poster VI RNA BIOMAR, 8:30 a.m.

Saturday, April 20, 2013
Oral Presentation

  • Abstract 126, Reference # 2279325: David Spetzler . Differential Protein Expression and MiR Content of Sorted Subsets of Circulating Microvesicles from Cancer Patients and Healthy Controls. Imperial Ballroom, Session 31, 11:15 a.m.


As part of Caris' presence at the 2013 ISEV meeting, a scientific symposium, Challenges and Opportunities in Advancing Solid and Blood-Based Tumor Profiling, is also planned for Wednesday, April 17, at 6 p.m. This symposium will feature presentations by the following Caris Life Sciences scientific experts:

  • Joachim Schorr , Ph.D., Chief Scientific Officer – Opportunities in blood-based tumor profiling
  • David Spetzler , Ph.D., MBA, MS, Vice President, Research and Development – Requirements for utilizing cMVs in the clinical standardization and stabilization of sample preparation
  • Zoran Gatalica , M.D., DSc, Medical Director – Personalized molecular medicine today

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. Caris' Molecular Intelligence™ Service (MI Profile™) correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.

 


'/>"/>
SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
2. PolyScience Heated Circulating Baths Boast Temperature Stabilities as Precise as ±0.005°C
3. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018: Transparency Market Research
4. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
7. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
8. New Bed Bug Bill Submitted and Complimentary Samples of Non-Pesticide Bed Bug Spray Presented to Help Landlords and Tenants, My Cleaning Products Shares the Details
9. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
10. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
11. 10 Fastest Ways to Land a Medical Sales Job Presented by Nationally Renowned Career Coach, Peggy McKee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
Breaking Biology News(10 mins):